336 related articles for article (PubMed ID: 30449485)
1. Differences in PD-L1 expression on tumor and immune cells between lung metastases and corresponding primary tumors.
Takamori S; Takada K; Tagawa T; Toyokawa G; Hirai F; Yamashita N; Okamoto T; Oki E; Yoshizumi T; Oda Y; Maehara Y
Surg Oncol; 2018 Dec; 27(4):637-641. PubMed ID: 30449485
[TBL] [Abstract][Full Text] [Related]
2. Cytologic-histologic correlation of programmed death-ligand 1 immunohistochemistry in lung carcinomas.
Russell-Goldman E; Kravets S; Dahlberg SE; Sholl LM; Vivero M
Cancer Cytopathol; 2018 Apr; 126(4):253-263. PubMed ID: 29405663
[TBL] [Abstract][Full Text] [Related]
3. Correlation Between Programmed Death Receptor-1 Expression in Tumor-Infiltrating Lymphocytes and Programmed Death Ligand-1 Expression in Non-Small Cell Lung Carcinoma.
Del C Monroig-Bosque P; Driver B; Morales-Rosado JA; Deavers M; Tacha D; Bernicker E; Cagle PT; Miller RA
Arch Pathol Lab Med; 2018 Nov; 142(11):1388-1393. PubMed ID: 29431467
[TBL] [Abstract][Full Text] [Related]
4. Significance of PD-L1 expression in pulmonary metastases from head and neck squamous cell carcinoma.
Okada S; Itoh K; Ishihara S; Shimada J; Kato D; Tsunezuka H; Miyata N; Hirano S; Teramukai S; Inoue M
Surg Oncol; 2018 Jun; 27(2):259-265. PubMed ID: 29937180
[TBL] [Abstract][Full Text] [Related]
5. PD-L1 expression on tumor-infiltrating immune cells is highly associated with M2 TAM and aggressive malignant potential in patients with resected non-small cell lung cancer.
Sumitomo R; Hirai T; Fujita M; Murakami H; Otake Y; Huang CL
Lung Cancer; 2019 Oct; 136():136-144. PubMed ID: 31499335
[TBL] [Abstract][Full Text] [Related]
6. Frequent discordance in PD-1 and PD-L1 expression between primary breast tumors and their matched distant metastases.
Manson QF; Schrijver WAME; Ter Hoeve ND; Moelans CB; van Diest PJ
Clin Exp Metastasis; 2019 Feb; 36(1):29-37. PubMed ID: 30547271
[TBL] [Abstract][Full Text] [Related]
7. Temporal and spatial discordance of programmed cell death-ligand 1 expression and lymphocyte tumor infiltration between paired primary lesions and brain metastases in lung cancer.
Mansfield AS; Aubry MC; Moser JC; Harrington SM; Dronca RS; Park SS; Dong H
Ann Oncol; 2016 Oct; 27(10):1953-8. PubMed ID: 27502709
[TBL] [Abstract][Full Text] [Related]
8. Heterogeneity of Tumor and Immune Cell PD-L1 Expression and Lymphocyte Counts in Surgical NSCLC Samples.
Casadevall D; Clavé S; Taus Á; Hardy-Werbin M; Rocha P; Lorenzo M; Menéndez S; Salido M; Albanell J; Pijuan L; Arriola E
Clin Lung Cancer; 2017 Nov; 18(6):682-691.e5. PubMed ID: 28549836
[TBL] [Abstract][Full Text] [Related]
9. Programmed Cell Death Ligand (PD-L1) Expression in Stage II and III Lung Adenocarcinomas and Nodal Metastases.
Uruga H; Bozkurtlar E; Huynh TG; Muzikansky A; Goto Y; Gomez-Caraballo M; Hata AN; Gainor JF; Mark EJ; Engelman JA; Lanuti MD; Mino-Kenudson M
J Thorac Oncol; 2017 Mar; 12(3):458-466. PubMed ID: 27815126
[TBL] [Abstract][Full Text] [Related]
10. PD-1 and PD-L1 expression in rare lung tumors.
Gyulai M; Megyesfalvi Z; Reiniger L; Harko T; Ferencz B; Karsko L; Agocs L; Fillinger J; Dome B; Szallasi Z; Moldvay J
Pathol Oncol Res; 2023; 29():1611164. PubMed ID: 37274772
[No Abstract] [Full Text] [Related]
11. An integrated biomarker of PD-L1 expression and intraepithelial CD8
Li LL; Zhou DX; Lu M; Zhou D; Lin XF; Chen Y; Yin K; Feng HB; Guo WB; Xie Z; Yan WQ; Lv ZY; Lu DX; Zhang SL; Zhang XC
Thorac Cancer; 2022 Jul; 13(13):1948-1960. PubMed ID: 35596539
[TBL] [Abstract][Full Text] [Related]
12. PD-L1 Expression of Lung Cancer Cells, Unlike Infiltrating Immune Cells, Is Stable and Unaffected by Therapy During Brain Metastasis.
Téglási V; Pipek O; Lózsa R; Berta K; Szüts D; Harkó T; Vadász P; Rojkó L; Döme B; Bagó AG; Tímár J; Moldvay J; Szállási Z; Reiniger L
Clin Lung Cancer; 2019 Sep; 20(5):363-369.e2. PubMed ID: 31178388
[TBL] [Abstract][Full Text] [Related]
13. Transition of the programmed death 1 pathway from the primary colorectal cancer to its corresponding pulmonary metastasis.
Miyamoto E; Chen-Yoshikawa TF; Ueshima C; Yoshizawa A; Hamaji M; Yamamoto T; Kawada K; Haga H; Sakai Y; Date H
J Surg Oncol; 2018 Jun; 117(7):1405-1412. PubMed ID: 29663398
[TBL] [Abstract][Full Text] [Related]
14. Programmed death-ligand 1 (PD-L1) expression in pleomorphic carcinoma of the lung.
Imanishi N; Hirai A; Yoneda K; Shimajiri S; Kuwata T; Tashima Y; Takeuchi M; Iwai Y; Ichiki Y; Tanaka F
J Surg Oncol; 2018 Jun; 117(7):1563-1569. PubMed ID: 29601633
[TBL] [Abstract][Full Text] [Related]
15. Immunohistochemical comparison of three programmed death-ligand 1 (PD-L1) assays in triple-negative breast cancer.
Yoshikawa K; Ishida M; Yanai H; Tsuta K; Sekimoto M; Sugie T
PLoS One; 2021; 16(9):e0257860. PubMed ID: 34559865
[TBL] [Abstract][Full Text] [Related]
16. Stromal PD-1/PD-L1 Expression Predicts Outcome in Colon Cancer Patients.
Wyss J; Dislich B; Koelzer VH; Galván JA; Dawson H; Hädrich M; Inderbitzin D; Lugli A; Zlobec I; Berger MD
Clin Colorectal Cancer; 2019 Mar; 18(1):e20-e38. PubMed ID: 30389315
[TBL] [Abstract][Full Text] [Related]
17. The immune microenvironment and expression of PD-L1, PD-1, PRAME and MHC I in salivary duct carcinoma.
Xu B; Jungbluth AA; Frosina D; Alzumaili B; Aleynick N; Slodkowska E; Higgins K; Ho A; Morris L; Ghossein R; Katabi N
Histopathology; 2019 Nov; 75(5):672-682. PubMed ID: 31237963
[TBL] [Abstract][Full Text] [Related]
18. Clinicopathological implications of the expression of vascular endothelial growth factor and programmed death ligand 1 in clear-cell renal cell carcinoma.
Lee KS; Yun S; Lee K; Moon S; Choe G
Hum Pathol; 2020 May; 99():88-97. PubMed ID: 32246989
[TBL] [Abstract][Full Text] [Related]
19. Clinicopathological correlation of PD-L1 expression in primary and metastatic breast cancer and infiltrating immune cells.
Tawfik O; Kimler BF; Karnik T; Shehata P
Hum Pathol; 2018 Oct; 80():170-178. PubMed ID: 29936058
[TBL] [Abstract][Full Text] [Related]
20. Program Death 1 Immune Checkpoint and Tumor Microenvironment: Implications for Patients With Intrahepatic Cholangiocarcinoma.
Gani F; Nagarajan N; Kim Y; Zhu Q; Luan L; Bhaijjee F; Anders RA; Pawlik TM
Ann Surg Oncol; 2016 Aug; 23(8):2610-7. PubMed ID: 27012989
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]